BACKGROUND: Human phosphodiesterase (PDE) type 8B (PDE8B) is located at 5q14.1 and is known as the PDE with the highest affinity to cAMP. We recently described a family with bilateral micronodular adrenocortical disease that was apparently caused by an inactivating PDE8B mutation (H305P). As a result of a genome-wide study, a strong association between six polymorphic variants in the PDE8B promoter and serum levels of the thyroid-stimulating hormone (TSH) has been recently reported. Despite an extended analysis of the regions surrounding 5q14.1, no other potential genetic variants that could be responsible for the associated TSH levels were found. METHODS: In this study, we genotyped by polymerase chain reaction the described six polymorphic variants in the PDE8B promoter in the family with micronodular adrenocortical disease and inactivating PDE8B mutation and analyzed their correlation with individual TSH values in the family members. RESULTS: We observed complete segregation between the reported association and individual TSH values in the family we studied. Haplotype analysis showed that the haplotype associated with the high TSH levels is different from the one that segregated with H305P, suggesting that the mutation most probably has arisen on an allele independent of the high TSH-associated allele. CONCLUSIONS: The proposed mechanism by which PDE8B may influence TSH levels is through control of cAMP signaling. Our analysis revealed separate segregation of an inactivating PDE8B allele from the high-TSH-allele and showed low TSH levels in persons who carry an inactivating PDE8B allele. These data suggest that, indeed, PDE8B may be involved in regulation of TSH levels.
BACKGROUND:Human phosphodiesterase (PDE) type 8B (PDE8B) is located at 5q14.1 and is known as the PDE with the highest affinity to cAMP. We recently described a family with bilateral micronodular adrenocortical disease that was apparently caused by an inactivating PDE8B mutation (H305P). As a result of a genome-wide study, a strong association between six polymorphic variants in the PDE8B promoter and serum levels of the thyroid-stimulating hormone (TSH) has been recently reported. Despite an extended analysis of the regions surrounding 5q14.1, no other potential genetic variants that could be responsible for the associated TSH levels were found. METHODS: In this study, we genotyped by polymerase chain reaction the described six polymorphic variants in the PDE8B promoter in the family with micronodular adrenocortical disease and inactivating PDE8B mutation and analyzed their correlation with individual TSH values in the family members. RESULTS: We observed complete segregation between the reported association and individual TSH values in the family we studied. Haplotype analysis showed that the haplotype associated with the high TSH levels is different from the one that segregated with H305P, suggesting that the mutation most probably has arisen on an allele independent of the high TSH-associated allele. CONCLUSIONS: The proposed mechanism by which PDE8B may influence TSH levels is through control of cAMP signaling. Our analysis revealed separate segregation of an inactivating PDE8B allele from the high-TSH-allele and showed low TSH levels in persons who carry an inactivating PDE8B allele. These data suggest that, indeed, PDE8B may be involved in regulation of TSH levels.
Authors: Amber E Baum; Leah C Solberg; Peter Kopp; Nasim Ahmadiyeh; Gary Churchill; Joseph S Takahashi; J Larry Jameson; Eva E Redei Journal: Endocrinology Date: 2004-10-28 Impact factor: 4.736
Authors: Giuseppe Pilia; Wei-Min Chen; Angelo Scuteri; Marco Orrú; Giuseppe Albai; Mariano Dei; Sandra Lai; Gianluca Usala; Monica Lai; Paola Loi; Cinzia Mameli; Loredana Vacca; Manila Deiana; Nazario Olla; Marco Masala; Antonio Cao; Samer S Najjar; Antonio Terracciano; Timur Nedorezov; Alexei Sharov; Alan B Zonderman; Gonçalo R Abecasis; Paul Costa; Edward Lakatta; David Schlessinger Journal: PLoS Genet Date: 2006-07-10 Impact factor: 5.917
Authors: Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis Journal: Endocr Rev Date: 2013-12-05 Impact factor: 19.871
Authors: Peter N Taylor; Vijay Panicker; Adrian Sayers; Beverley Shields; Ahmed Iqbal; Alexandra P Bremner; John P Beilby; Peter J Leedman; Andrew T Hattersley; Bijay Vaidya; Timothy Frayling; Jonathan Evans; Jonathan H Tobias; Nicholas J Timpson; John P Walsh; Colin M Dayan Journal: Eur J Endocrinol Date: 2011-02-11 Impact factor: 6.664
Authors: Jennifer R Malinowski; Joshua C Denny; Suzette J Bielinski; Melissa A Basford; Yuki Bradford; Peggy L Peissig; David Carrell; David R Crosslin; Jyotishman Pathak; Luke Rasmussen; Jennifer Pacheco; Abel Kho; Katherine M Newton; Rongling Li; Iftikhar J Kullo; Christopher G Chute; Rex L Chisholm; Gail P Jarvik; Eric B Larson; Catherine A McCarty; Daniel R Masys; Dan M Roden; Mariza de Andrade; Marylyn D Ritchie; Dana C Crawford Journal: PLoS One Date: 2014-12-01 Impact factor: 3.240